(Received for publication May 21, 1975) Cefatrizine (SK&F 60771), a new orally-active semisynthetic cephalosporin antibiotic with broad-spectrum antibacterial activity, was compared with cephalexin and cefazolin for in vitro and in vivo antibacterial activity and pharmacokinetic behavior in laboratory animals. The average MIC values obtained with cefatrizine against gram-positive and gram-negative bacteria were superior to those obtained with cephalexin and somewhat poorer than those of cefazolin. In addition, a large percentage of the enterobacter and enterococcus isolates were found to be susceptible. Cefatrizine had a longer biological half-life and a higher peak serum level than either cefazolin or cephalexin when administered parenterally or orally to mice at 20 mg/kg. It had striking in vivo protective activity in mice infected with Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Hemophilus influenzae, Proteus morganii or Staphylococcus aureus reflecting its superior pharmacokinetic profile in this animal species. A variable pharmacokinetic response between animal species was observed when cefatrizine was administered either orally or parenterally to dogs, squirrel monkeys or rabbits. 
Efficacy Studies
Male albino Swiss-Webster mice weighing 18-20g were used for the efficacy studies . Cultures of the test organisms were diluted in either trypticase soy broth (Klebsiella) or 5 % hog gastric mucin and injected intraperitoneally to produce uniformly lethal mouse infections. Unless noted otherwise, test drugs were dissolved in isotonic sodium chloride solution and administered either orally or subcutaneously at 1 and 5 hours after infection. Final survival percentages for groups of 10 mice each, obtained after observation for 3 days, were used to estimate the ED50 (total mg/kg of antibiotic required to protect 50 % of the infected animals) and the LD50 values (dose of inoculum required to kill 50 % of the mice). The ED50 and LD50 values were determined by the method of LITCHFIELD and WILCOXON5). The minimum inhibitory concentrations (MIC) were determined by the agar dilution method as described previously6). The MIC values were determined on nutrient agar except for Streptococcus pneumoniae, Neisseria gonorrhoeae, N. meningitides and H. influenzae where the test medium was MUELLER-HINTON Agar fortified with IsoVitalex and Fildes enrichments and buffered with HEPES to pH 6.8.
Microbiological Assay
Disc-plate assays with Bacillus subtilis ATCC 6633 as the indicator organism were employed to determine serum and urine concentrations of the antibiotics. For serum assays, standard curves were prepared by plotting dose-response data for each antibiotic using pooled sera as diluent for the standard. For urine assays, standard curves were prepared in 0.01 N phosphate buffer (pH 6.0). Assay plates were incubated for 18 hours at 30°C. Zone diameters were measured with a Fisher-Lilly Zone Reader.
Pharmacokinetic Studies Serum levels in laboratory animals were determined at selected time intervals after oral or parenteral administration. The cephalosporins were dissolved in water using 5.7 % bicarbonate solution, if necessary, and adminstered orally or parenterally at a level of 20 mg/kg. Oral administration was via intubation except for dogs where the cephalosporin was administered in a gelatin capsule. Parenteral administration was via the intramuscular route except for mice who were dosed subcutaneously. Blood samples were obtained from mice by decapitation of duplicate pooled groups of 10 mice each. Sequential blood samples were drawn from the jugular vein in the dog, the femoral vein in the squirrel monkey, and the marginal ear vein in the rabbit. Blood samples were kept at 4°C until clotting occurred and the serum obtained after centrifugation was stored at -20°C prior to assay. The serum half-life after parenteral or oral administration was estimated from a semi-log plot of the antibiotic levels versus time. A crossover protocol was employed for all the studies involving dogs, squirrel monkeys and rabbits. Urinary antibiotic recovery during the four-hour period after dosing was determined in duplicate groups of ten mice. The mice were housed in metabolism cages and the urine was collected in bottles packed in dry ice. Dog urine samples were collected at 0-6 and 6-24 hours after administration. Dogs were catheterized at 6 hours to clear the bladder of unvoided urine. Voided urine was collected from metabolism pans into cold plastic containers. All urine samples were stored at -20°C prior to assay.
Results

In Vitro Studies
The minimum inhibitory concentrations obtained with cefatrizine, cephalexin and cefazolin against 174 bacterial isolates representing 10 genera are shown in These plots for cefatrizine, cephalexin and cefazolin clearly point up differences between the three antibiotics. Against all seven species, the poorest activity by far was observed with cephalexin. With the exception of enterobacter and enterococci, the intrinsic activity of cefazolin tended to be superior to that of cefatrizine; cefazolin was more active against strains of E. coli, K. pneumoniae, P. mirabilis and S. aureus. The enterobacter strains showed a wide variation in susceptibility to cefatrizine, however, this Table 3 lists the data obtained with the three cephalosporins in mice against four strains of E. cloacae and one strain of E, aerogenes. Minimum inhibitory concentration (mcg/ml) a single dose of cefatrizine adminstered up to 5 hours before infection, whereas cephalexin and cefazolin gave no protection at the levels tested (Table 5) . Similar results were obtained when the three antibiotics were administered in a single dose up to 5 hours after infection (Table 6 ). (Table 7) . In rabbits the pharmacokinetic profiles of cefatrizine and cephalexin after oral dosing were similar. In In mice, the urinary recovery of cefatrizine at four hours after oral administration was 24 % as compared with 55 % for cephalexin and 50 % for cefazolin. In the dog, urinary recovery of cefatrizine was 20 % at 24 hours post oral administration and 72 % for cephalexin.
When cefatrizine was compared to cefazolin following parenteral administration, a similar mixed response was observed in the four animal species examined (Table 8) . As was found for the oral administration, parenteral administration resulted in an enhanced pharmacokinetic profile in the mouse, whereas the other animal species showed a more variable response. The urinary recovery for cefatrizine in mice (23%) and dogs (18 %) was found to be lower than that of the control cefazolin (50% in mice, 68 % in dogs).
Discussion
Cefatrizine (SK&F 60771) was found to have potent antibacterial activity in vitro against a broad spectum of clinical isolates. The activity observed was two to eight fold better than that of cephalexin and approximately one-half that of cefazolin. Against enterobacter and enterococcus, cefatrizine was clearly more potent than either cephalexin or cefazolin. In mice this new cephalosporin is absorbed rapidly after oral administration and peak serum level (44 mcg/ml) is approximately twice that of cephalexin (24 mcg/ml). In addition, its half-life is markedly prolonged resulting in effective serum antibiotic concentrations (12.5 mcg/ml at 2 hours) after oral administration.
Similar high and extended serum levels were obtained in mice after subcutaneous administration.
This improved pharmacokinetic profile is in part responsible for the excellent protective activity observed after oral or subcutaneous administration to infected mice. Administration of cefatrizine even five hours prior to lethal challenge with E. coli resulted in excellent protection.
In untreated control animals infected with E. coli, death is usually observed within 18 hours after infection.
Despite this rapid course of infection, a single oral or subcutaneous dose of cefatrizine given at five hours post-infection protected the animals (ED 50 0.9 mg/kg). Under the severe conditions of this test, cephalexin and cefazolin were more than 25 times less active. Cefatrizine was effective against massive challenge with E. coli (10 6 LD50 administered IP), whereas, the other two cephalosporins failed to protect mice under the same conditions.
The serum levels obtained after oral or parenteral adminstration of cefatrizine were found to vary in different animal species. Although the data obtained in mice show elevated and sustained antibiotic serum levels with oral or parenteral cefatrizine, this was not always the case in the other animal species. In the rabbit the peak serum levels and half-lives were similar to cephalexin after oral administration and to cefazolin's after intramuscular administration. Oral administration of cefatrizine to squirrel monkeys resulted in low and prolonged serum levels, whereas the serum levels obtained with cephalexin were significantly higher. The wide variation in response in these animal species is not surprising as other cephalosporins have been shown to produce a mixed response in different animal species 7).
From the laboratory studies presented here, it is evident that SK&F 60771 is an unusual and interesting cephalosporin deserving further investigation.
